Information Provided By: 
Fly News Breaks for March 28, 2018
GMED
Mar 28, 2018 | 08:12 EDT
Leerink analyst Richard Newitter raised his price target for Globus Medical to $60 from $56 as he remains bullish on the stock given the two new product cycles - Robotics and Trauma - in the early stages, both with potential to drive upside even to his above-consensus out-year forecasts and capable of sustaining a low-teens top-line CAGR profile through 2020. The analyst reiterates an Outperform rating on the shares.
News For GMED From the Last 2 Days
There are no results for your query GMED
